The Company has a 2006 Equity Incentive Plan and an Amended and Restated 2015 Equity Incentive Plan. The 2015 plan, which was approved by the shareholders on April 24, 2015, replaced the 2006 plan. New grants may not be made under the 2006 plan; however certain option grants under these plans remain exercisable as of December 31, 2020. The aggregate number of shares of common stock for which awards could be granted under the 2015 plan as of the date of adoption was 500 shares. Additionally, as outstanding options under the 2006 plan or 2015 plan expire, terminate, are cancelled or forfeited or are withheld in a net exercise, the shares of the Company’s common stock subject to such options will become available for issuance under the 2015 plan. The 2015 plan was amended and restated in 2020 to reflect certain corporate governance changes and to increase the number of shares of common stock that could be awarded under the 2015 plan by 500 shares, subject to shareholder approval.

Under the plans, executives, employees and outside directors receive awards of restricted stock units (RSUs) and/or options to purchase common stock. The Company may also grant stock awards, stock appreciation rights, restricted stock and other equity-based awards, although no such awards, other than awards under the director program and management purchase program described below, had been granted as of December 31, 2020. Under all awards, the terms are fixed on the grant date. Generally, the exercise price of stock options equals the market price of the Company’s stock on the date of the grant. RSUs under the plans generally vest over three years. Options under the plans generally vest over three years, and have a maximum term of 10 years.

The Company granted 146 RSUs for the year ended December 31, 2020. The RSUs vest in equal, annual installments over a three-year period beginning on the first anniversary of the date of grant at which time common stock is issued with respect to vested units.



	Outstanding Awards
	Stock Options	RSUs	Total	Stock Option Weighted-Average ‎Exercise Price (a)		Aggregate ‎ Intrinsic Value
Outstanding at December 31, 2017	1,438	-	1,438	$	6.00
Awards forfeited or cancelled	(8)	-	(8)		7.20
Awards granted	-	98	98		-
Awards exercised or released	(600)	-	(600)		5.65
Outstanding at December 31, 2018	830	98	928		6.25
Awards forfeited or cancelled	(3)	(1)	(4)		6.42
Awards granted	-	79	79		-
Awards exercised or released	(81)	(48)	(129)		4.91
Outstanding at December 31, 2019	746	128	874	$	6.39
Awards forfeited or cancelled	(1)	(5)	(6)		5.72
Awards granted	-	146	146		-
Awards exercised or released	(55)	(52)	(107)		4.88
Outstanding at December 31, 2020	690	217	907	$	6.51	$	11,929

Exercisable at December 31, 2019	668		668	$	6.30	$	7,819

Exercisable at December 31, 2020	690		690	$	6.51	$	7,997

Available for future grant at December 31,2020	73

The number of shares available for future grant at December 31, 2020, does not include a total of up to 325 shares subject to options outstanding under the 2006 plan which will become available for grant under the 2015 plan as outstanding options under the 2006 plan expire, terminate, are cancelled or forfeited or are withheld in a net exercise of such options.

The weighted-average remaining contractual term of options exercisable and options outstanding at December 31, 2020 was 4 years. The total intrinsic value of options exercised during fiscal 2020, 2019, and 2018, was $514, $1,627, and $25,724, respectively. No options were issued in 2020, 2019 and 2018.

The weighted-average per share grant date fair value of restricted stock units granted was $14.92 in 2020 and $23.83 in 2019.

The Company recorded $2,382, $1,886, and $1,395 of non-cash stock compensation expense for the years ended December 31, 2020, 2019, and 2018, respectively. As of December 31, 2020, there was $1,650 of total non-cash stock compensation expense related to non-vested awards that is expected to be recognized over a weighted-average period of 1.95 years. During the year ended December 31, 2020, the Company recorded a cumulative non-cash stock compensation expense adjustment of $422 for individuals who are retirement eligible and therefore have vested in stock awards according to our plan. The adjustment was not material to our Consolidated Financial Statements.

The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, provides that a maximum of 300 shares may be sold under the Purchase Plan. There were 16, 9, and 7 shares purchased under the Purchase Plan during the years ended December 31, 2020, 2019, and 2018, respectively.